- Home
- OLMA
as 05-20-2024 10:34am EST
$.
-
$.
-.%
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 550.4M | IPO Year: | 2020 |
| Target Price: | $22.80 | AVG Volume (30 days): | 842.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.02 - $17.79 | Next Earning Date: | 05-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Olema Pharmaceuticals Inc. (OLMA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Harmon Cyrus | OLMA | Director | May 6 '24 | Sell | $10.92 | 5,000 | $54,600.00 | 806,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Feb 29 '24 | Sell | $12.41 | 24,900 | $309,009.00 | 846,383 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Feb 29 '24 | Sell | $13.00 | 100 | $1,300.00 | 846,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Nov 30 '23 | Sell | $12.57 | 25,000 | $314,250.00 | 926,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Nov 20 '23 | Sell | $13.90 | 3,989 | $55,447.10 | 951,283 | SEC Form 4 |
| Harmon Cyrus | OLMA | Director | Nov 20 '23 | Sell | $14.86 | 4,192 | $62,293.12 | 955,272 | SEC Form 4 |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Nov 20 '23 | Sell | $14.83 | 7,261 | $107,680.63 | 37,959 | SEC Form 4 |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Nov 20 '23 | Sell | $15.33 | 200 | $3,066.00 | 37,759 | SEC Form 4 |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Nov 20 '23 | Sell | $13.89 | 7,095 | $98,549.55 | 30,664 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 '23 | Sell | $14.87 | 6,776 | $100,759.12 | 580,952 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 '23 | Sell | $15.32 | 200 | $3,064.00 | 580,752 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 '23 | Sell | $13.89 | 6,653 | $92,410.17 | 574,099 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 8 '23 | Sell | $17.61 | 200 | $3,522.00 | 561,270 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 1 '23 | Sell | $15.02 | 6,668 | $100,153.36 | 565,343 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 1 '23 | Sell | $15.36 | 3,332 | $51,179.52 | 562,011 | SEC Form 4 |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Nov 1 '23 | Sell | $17.51 | 541 | $9,472.91 | 561,470 | SEC Form 4 |
| Graham G. Walmsley | OLMA | Director | Sep 12 '23 | Buy | $9.84 | 508,130 | $4,999,999.20 | 1,668,130 | SEC Form 4 |
| Graham G. Walmsley | OLMA | Director | Sep 12 '23 | Buy | $14.73 | 31,870 | $469,550.27 | 1,700,000 | SEC Form 4 |
| Graham G. Walmsley | OLMA | Director | Sep 12 '23 | Buy | $14.95 | 50,000 | $747,480.00 | 1,750,000 | SEC Form 4 |
| Graham G. Walmsley | OLMA | Director | Sep 12 '23 | Buy | $13.09 | 50,000 | $654,250.00 | 1,800,000 | SEC Form 4 |
Latest Olema Pharmaceuticals Inc. News
OLMA Breaking Stock News: Dive into OLMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
GlobeNewswire
12 days ago
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
12 days ago
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
GlobeNewswire
18 days ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
19 days ago
Olema Oncology to Participate in Upcoming Investor Conferences in May
GlobeNewswire
a month ago
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
TipRanks
a month ago
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
2 months ago